Regeneron Pharmaceuticals, headquartered in Tarrytown, New York, focuses on developing medicines for serious diseases, employing 13,450 people. Its key products include EYLEA, Dupixent, and Libtayo, utilizing advanced technologies like VelociSuite.
REGN has been in the news recently: The FDA plans to enhance unannounced inspections of foreign facilities producing food and essential medicines, potentially impacting companies like Regeneron Pharmaceuticals. Currently, Regeneron's stock is priced at $563.91, reflecting a recent increase but a significant decline of 41.74% over the past year.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
